Corcept Therapeutics Inc CORT
We take great care to ensure that the data presented and summarized in this overview for CORCEPT THERAPEUTICS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CORT
View all-
Black Rock Inc. New York, NY16.5MShares$1.17 Billion0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.98MShares$704 Million0.02% of portfolio
-
Ingalls & Snyder LLC New York, NY7.74MShares$546 Million29.09% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny6.14MShares$434 Million1.13% of portfolio
-
Parallel Advisors, LLC3.97MShares$280 Million5.04% of portfolio
-
State Street Corp Boston, MA3.4MShares$240 Million0.02% of portfolio
-
Geode Capital Management, LLC Boston, MA2.26MShares$159 Million0.02% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.14MShares$151 Million0.06% of portfolio
-
Morgan Stanley New York, NY1.54MShares$109 Million0.01% of portfolio
-
Arrowstreet Capital, Limited Partnership Boston, MA1.49MShares$105 Million0.14% of portfolio
Latest Institutional Activity in CORT
Top Purchases
Top Sells
About CORT
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
Insider Transactions at CORT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 10
2025
|
William Guyer Chief Development Officer |
SELL
Open market or private sale
|
Direct |
20,000
-51.17%
|
$1,440,000
$72.56 P/Share
|
|
Jun 10
2025
|
William Guyer Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+43.97%
|
$420,000
$21.65 P/Share
|
|
Jun 10
2025
|
Daniel N Swisher Jr |
SELL
Open market or private sale
|
Direct |
2,200
-100.0%
|
$154,000
$70.61 P/Share
|
|
Jun 10
2025
|
Daniel N Swisher Jr |
BUY
Exercise of conversion of derivative security
|
Direct |
2,200
+50.0%
|
$30,800
$14.08 P/Share
|
|
Jun 03
2025
|
Atabak Mokari Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
519
-3.56%
|
$36,849
$71.68 P/Share
|
|
Jun 03
2025
|
Gary Charles Robb Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
651
-3.78%
|
$46,221
$71.68 P/Share
|
|
Jun 03
2025
|
Joseph Douglas Lyon |
SELL
Payment of exercise price or tax liability
|
Direct |
441
-4.2%
|
$31,311
$71.68 P/Share
|
|
Jun 02
2025
|
Joseph K Belanoff Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
40,000
-0.17%
|
$3,240,000
$81.85 P/Share
|
|
Jun 02
2025
|
Atabak Mokari Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,550
+5.18%
|
$54,250
$35.84 P/Share
|
|
Jun 02
2025
|
Gary Charles Robb Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,994
+5.64%
|
$69,790
$35.84 P/Share
|
|
Jun 02
2025
|
Sean Maduck |
SELL
Open market or private sale
|
Direct |
20,000
-17.04%
|
$1,580,000
$79.36 P/Share
|
|
Jun 02
2025
|
Sean Maduck |
BUY
Grant, award, or other acquisition
|
Direct |
21,776
+14.82%
|
$544,400
$25.58 P/Share
|
|
Jun 02
2025
|
Joseph Douglas Lyon |
BUY
Grant, award, or other acquisition
|
Direct |
1,498
+6.89%
|
$52,430
$35.84 P/Share
|
|
Jun 02
2025
|
Joseph Douglas Lyon |
SELL
Open market or private sale
|
Direct |
5,000
-18.57%
|
$390,000
$78.31 P/Share
|
|
Jun 02
2025
|
Joseph Douglas Lyon |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+26.3%
|
$65,000
$13.56 P/Share
|
|
May 29
2025
|
Sean Maduck |
BUY
Other acquisition or disposition
|
Indirect |
10,000
+10.03%
|
-
|
|
May 29
2025
|
Sean Maduck |
SELL
Bona fide gift
|
Direct |
10,000
-38.57%
|
-
|
|
May 29
2025
|
Sean Maduck |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+27.83%
|
$30,000
$3.88 P/Share
|
|
May 20
2025
|
Gary Charles Robb Chief Business Officer |
BUY
Bona fide gift
|
Indirect |
720
+3.02%
|
-
|
|
May 20
2025
|
Gary Charles Robb Chief Business Officer |
SELL
Bona fide gift
|
Direct |
1,380
-8.32%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 1.57M shares |
|---|---|
| Grant, award, or other acquisition | 34.3K shares |
| Bona fide gift | 6.29K shares |
| Other acquisition or disposition | 157K shares |
| Payment of exercise price or tax liability | 490K shares |
|---|---|
| Open market or private sale | 795K shares |
| Bona fide gift | 182K shares |
| Other acquisition or disposition | 8.25K shares |